步长制药双获殊荣：创新研发与公益担当引领大健康产业发展新标杆

Core Insights - The company, Buchang Pharma, has been awarded "Annual Drug R&D Innovation Enterprise" and "Annual Excellent Public Welfare Enterprise" at the 2025 9th Century Health Industry Competitiveness Research "Sunshine" Case, highlighting its dual leadership in drug innovation and social responsibility [1][6] Group 1: Innovation and R&D - Buchang Pharma's recognition as "Annual Drug R&D Innovation Enterprise" is a result of over 30 years of commitment to the pharmaceutical industry, with innovation as its core development engine [2] - The company announced a strategic transformation in 2018, shifting from a marketing-driven model to a product and technology-driven approach, expanding from traditional Chinese medicine to biopharmaceuticals, chemical drugs, and medical devices [2] - In 2024, the company's R&D investment reached 717 million yuan, an increase of 8.58% year-on-year, with a focus on both independent innovation and collaborative research [2] - As of mid-2025, Buchang Pharma holds 457 valid patents and has over 200 products in development, laying a solid foundation for industry-wide innovation [2] Group 2: Product Portfolio - The company has established a product portfolio that covers major disease areas, including cardiovascular, gynecological, urological, diabetes, and oncology [3] - Key proprietary products, including Naoxin Tong Capsule, Stabilizing Heart Granules, and Danhong Injection, generated sales of 5.83 billion yuan in 2024 and 3.12 billion yuan in the first half of 2025, ranking in the top five in the cardiovascular traditional Chinese medicine market [3] - These key products are included in the 2024 National Medical Insurance Directory, ensuring reimbursement support and facilitating market share expansion [3] Group 3: Social Responsibility and Public Welfare - The company has been actively engaged in public welfare for over 20 years, focusing on social responsibility as a core component of its business strategy [6] - The "Together to Build a Chinese Heart" project has provided assistance to over 100 million people in Tibetan and other underdeveloped regions, showcasing the company's commitment to healthcare and community support [6][7] - Buchang Pharma's public welfare initiatives are integrated with its business strategy, enhancing brand recognition and expanding market reach while addressing healthcare needs in underserved areas [8] - Since its establishment, the company has contributed nearly 33 billion yuan in taxes, supporting local economic development [8]